Gov. Martin O'Malley joined the governors of Delaware and West Virginia to discuss how states have found biopharmaceutical research companies to be an important source of jobs, tax revenue and research spending.
O'Malley took part in a clinical trials forum with Delaware Gov. Jack Markell and West Virginia Gov. Earl Ray Tomblin to talk about the benefits of clinical trials from a state-based perspective.
The Pharmaceutical Research and Manufacturers of America also released a report titled "Research in Your Backyard: Developing Cures, Creating Jobs." The report found that biopharmaceutical research companies in Maryland are conducting or have conducted nearly 3,500 clinical trials of new medicines since 1999. Of those, 1,775 target the nation's six most debilitating chronic diseases: asthma, cancer, diabetes, heart disease, mental illnesses and stroke.
"The biotechnology industry continues to make groundbreaking discoveries due to Maryland's continued investments in our workforce, our higher education system and in the programs that have helped our emerging companies to succeed," O'Malley said.
The forum, which will take place at the University of Maryland, Baltimore BioPark, was co-sponsored by the Pharmaceutical Research and Manufacturers of America and the Maryland chapter of We Work for Health.